GSA Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,688
| Closed | -$881K | – | 2016 |
|
|
2026
Q1 | $881K | Buy |
6,688
+2,914
| +77% | +$387K | 0.05% | 554 |
|
|
2025
Q4 | $535K | Buy |
3,774
+1,387
| +58% | +$201K | 0.05% | 763 |
|
|
2025
Q3 | $335K | Buy |
+2,387
| New | +$323K | 0.03% | 1136 |
|
|
2025
Q2 | – | Sell |
-2,667
| Closed | -$295K | – | 2006 |
|
|
2025
Q1 | $295K | Buy |
+2,667
| New | +$338K | 0.03% | 1167 |
|
|
2024
Q4 | – | Sell |
-8,682
| Closed | -$1M | – | 1878 |
|
|
2024
Q3 | $1M | Buy |
8,682
+7,078
| +441% | +$970K | 0.08% | 471 |
|
|
2024
Q2 | $221K | Buy |
+1,604
| New | +$220K | 0.02% | 1424 |
|
|
2023
Q4 | – | Sell |
-1,964
| Closed | -$221K | – | 1768 |
|
|
2023
Q3 | $221K | Sell |
1,964
-482
| -20% | -$50.8K | 0.02% | 1240 |
|
|
2023
Q2 | $231K | Buy |
+2,446
| New | +$239K | 0.02% | 1190 |
|
|
2023
Q1 | – | Sell |
-12,189
| Closed | -$1.46M | – | 1780 |
|
|
2022
Q4 | $1.46M | Buy |
12,189
+8,386
| +221% | +$982K | 0.18% | 75 |
|
|
2022
Q3 | $404K | Sell |
3,803
-1,323
| -26% | -$134K | 0.05% | 734 |
|
|
2022
Q2 | $500K | Buy |
+5,126
| New | +$473K | 0.08% | 503 |
|
|
2021
Q4 | – | Sell |
-4,890
| Closed | -$469K | – | 1659 |
|
|
2021
Q3 | $469K | Buy |
+4,890
| New | +$462K | 0.05% | 734 |
|
|
2020
Q4 | – | Sell |
-7,081
| Closed | -$681K | – | 1474 |
|
|
2020
Q3 | $681K | Buy |
7,081
+5,415
| +325% | +$626K | 0.11% | 246 |
|
|
2020
Q2 | $203K | Buy |
+1,666
| New | +$184K | 0.11% | 344 |
|
|
2020
Q1 | – | Sell |
-14,569
| Closed | -$1.57M | – | 1380 |
|
|
2019
Q4 | $1.57M | Buy |
14,569
+9,440
| +184% | +$988K | 0.18% | 59 |
|
|
2019
Q3 | $462K | Sell |
5,129
-4,571
| -47% | -$427K | 0.06% | 603 |
|
|
2019
Q2 | $819K | Buy |
9,700
+2,800
| +41% | +$230K | 0.09% | 350 |
|
|
2019
Q1 | $608K | Sell |
6,900
-3,500
| -34% | -$293K | 0.06% | 575 |
|
|
2018
Q4 | $743K | Buy |
10,400
+5,562
| +115% | +$533K | 0.09% | 352 |
|
|
2018
Q3 | $595K | Buy |
+4,838
| New | +$549K | 0.03% | 985 |
|
|
2018
Q2 | – | Sell |
-2,431
| Closed | -$202K | – | 1848 |
|
|
2018
Q1 | $202K | Buy |
+2,431
| New | +$205K | 0.01% | 1467 |
|
|
2016
Q1 | – | Sell |
-5,718
| Closed | -$323K | – | 1830 |
|
|
2015
Q4 | $323K | Sell |
5,718
-35,648
| -86% | -$1.81M | 0.02% | 1422 |
|
|
2015
Q3 | $1.65M | Buy |
41,366
+30,150
| +269% | +$1.46M | 0.08% | 359 |
|
|
2015
Q2 | $536K | Sell |
11,216
-96
| -0.8% | -$4.07K | 0.02% | 1317 |
|
|
2015
Q1 | $449K | Buy |
+11,312
| New | +$405K | 0.02% | 1465 |
|
|
2014
Q3 | – | Sell |
-17,211
| Closed | -$255K | – | 1861 |
|
|
2014
Q2 | $255K | Buy |
+17,211
| New | +$243K | 0.01% | 1500 |
|
Other funds holding NBIX
GSA Capital Partners's NBIX Position: Q2 2026 in Review
GSA Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 6,688 shares — an estimated $881K sold.
GSA Capital Partners first reported a position in NBIX in Q2 2014 and held it in 26 quarters. The position peaked at $1.65M in Q3 2015. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- GSA Capital Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
- GSA Capital Partners sold 6,688 Neurocrine Biosciences shares in Q2 2026, an estimated $881K.
- GSA Capital Partners first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 26 quarters.
- GSA Capital Partners's Neurocrine Biosciences position peaked at $1.65M in Q3 2015.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.